Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes

Current Medical Research and Opinion

Volumn 23, Issue 4, 2007, Pages 919-931

  Pratley, Richard E ^a   Salsali, Afshin ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

DPP 4 inhibitor; GLP 1; Incretin mimetic; Incretins; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; PHX 1149; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET; DISEASE COURSE; DRUG ABSORPTION; DRUG BINDING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MEDICAL SOCIETY; MEDLINE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PATHOGENESIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; VOMITING;

ADAMANTANE; ADENOSINE DEAMINASE; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLYCOPROTEINS; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; PYRAZINES; TRIAZOLES;

EID: 34247362355     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X162746     Document Type: Review

References (104)

1. International Diabetes Federation (IDF). Diabetes Atlas 2003. Available at: http://www.eatlas.idf.org/prevalence. Accessed March 17, 2006
2. CDC. National Diabetes Fact Sheet, 2005. US Department of Health and Human Services, 2005. Available at: http://www.cdc.gov/diabetes/pubs/factsheet. htm. Accessed March 17, 2006
3. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
4. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease: UKPDS 16. Diabetes 1995;44:1249-58
5. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes. Expert Opin Investig Drugs 2004;13:1091-102
6. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006;29:435-49
7. Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 2004;36:775-81
8. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-76
9. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94
10. Efendic S, Portwood N. Overview of incretin hormones. Horm Metab Res 2004;36:742-6
11. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr 2004;17:183-90
12. DeFronzo RA. Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance? Br J Diabetes Vasc Dis 2003;3(Suppl 1):S24-40
13. Ahrén B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab 2005;7:2-8
14. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-15
15. Yoon KH, Ko SH, Cho JH, et al. Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003;88:2300-8
16. Butler AE, Janson J, Soeller WC, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10
17. Ørskov C, Holst JJ, Knuhtsen S, et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986;119:1467-75
18. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;2:616-19
19. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide 1, an insulin releasing hormone from the distal gut. FEBS Lett 1987;211:169-74
20. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123:2009-13
21. Fridolf T, Bottcher G, Sundler F, Ahren B. GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 1991;6:208-15
22. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002;18:430-41
23. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-8
24. Ørskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996;31:665-70
25. Edwards CM, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48:86-93
26. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocrine Rev 1999;20:876-913
27. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995;16:390-410
28. Scrocchi LA, Brown TJ, MacLusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996;2:1254-8
29. Lewis JT, Dayanandan B, Habener JF, Kieffer TJ. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology 2000;141:3710-16
30. Tseng CC, Zhang XY, Wolfe MM. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol 1999;276:E1049-54
31. Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357-66
32. Kolligs F, Fehmann HC, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995;44:16-19
33. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23
34. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994;51:63-74
35. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7
36. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40
37. Holst JJ, Ørskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 2004;53(Suppl 3):S197-204
38. Creutzfeldt W. The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 2001:109(Suppl 2):S288-303
39. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4
40. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992;130:159-66
41. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type 1 diabetic patients. Diabetes Care 1996;19:580-6
42. Nauck MA, Kleine N, Ørskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4
43. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004;36:747-54
44. Holz GG. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta cells. Horm Metab Res 2004;36:787-94
45. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
46. Gault VA, Parker JC, Harriott P, et al. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP (3-42), is a GIP receptor antagonist in vivo. J Endocrinol 2002;175:525-33
47. Quddusi S, Vahl TP, Hanson K, et al. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first-and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003;26;791-8
48. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40
49. Hughes T, Russel ME, Bolognese L, et al. NVP-LAF237, a highly selective and long-acting dipeptidyl peptidase IV inhibitor. Diabetes 2002;51 (Suppl 2):A67. Abstract 272-OR
50. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47:1663-70
51. Deacon CF, Nauck MA, Meier J, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575-81
52. Vilsbøll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4
53. Reimer MK, Holst JJ, Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002;146:717-27
54. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004;36:852-8
55. Ahrén B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84
56. Dungan K, Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes 2005;23:56-62
57. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc., 2006
58. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
59. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;2:1083-91
60. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
61. Zinman B, Hoogwerf B, Garcia S, et al. Safety and efficacy of exenatide in patients with type 2 diabetes mellitus using thiazolidinediones with or without metformin. Diabetes 2006;55(Suppl 1):A28. Abstract 117-OR
62. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81
63. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7
64. Holst JJ, Ørskov C. The incretin approach for diabetes treatment. Modulation of islet hormone release by GLP-1 agonism. Diabetes 2004;53(Suppl 3):S197-204
65. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424-9
66. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a double-blind, 12-week, randomized, controlled trial. Diabetes Care 2004;27:1335-42
67. Ahrén B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000;404:239-45
68. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998;47:764-9
69. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005;48:616-20
70. Mendein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
71. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005;1:22-31
72. Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases apoptosis. Diabetes 2005;54(Suppl 1):A141. Abstract P572
73. Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase I/V improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75
74. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxyl-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89
75. He YL, Sabo R, Wang Y. Influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharm Ther 2006;79:P63. Abstract PIII-19
76. He YL, Barilla D, Ligueros-Saylan M, et al. The pharmacokinetics and DPP-4 inhibition of LAF237 in healthy volunteers. J Clin Pharmacol 2004;44:1212. Abstract 16
77. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed B-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94
78. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8
79. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-8
80. Dejager S, Baron MA, Razac S, et al. Efficacy of vildagliptin in drug-naïve patients with type 2 diabetes. Diabetologia 2006;49(Suppl 1):479. Abstract 0791
81. 1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A29. Abstract 120-OR
82. 1c but without weight gain in drug-naïve patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A132. Abstract 557-P
83. Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus. Presented at: American Diabetes Association - 66th Scientific Sessions, Washington, DC, June 13, 2006
84. Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80
85. Garber A, Camisasca RP, Ehrsam E, et al. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A29. Abstract 121-OR
86. Baron MA, Rosenstock J, Bassiri B, et al. Efficacy of vildagliptin combined with pioglitazone in patients with type 2 diabetes. Diabetologia 2006;49(Suppl 1):485. Abstract 0801
87. Fonseca V, Dejager S, Albrecht D, et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A111. Abstract 467-P
88. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoremethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:1141-51
89. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006;46:876-86
90. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients widi type 2 diabetes. J Clin Endocrinol Metab 2006; J Clin Endocrinol Metab 2006;91:4612-9
91. Herman G, Hanefeld M, Wu M, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-JV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 2005;54(Suppl 1):A134. Abstract 541-P
92. Medicalnewstoday.com. Sitagliptin (MK-0431) for Type 2 Diabetes shows promise in Phase II clinical trials. 11 June 2005. Available at: http://medicalnewstoday.com/medicalnews.php?newsid=25962. Accessed August 24, 2006
93. Scott R, Herman G, Zhao P, et al. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D). Diabetes 2005;54(Suppl 1):A10. Abstract 41-OR
94. Aschner P, Kipnes M, Lunceford J, et al. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A462. Abstract 1995-PO
95. Karasik A, Charbonnel B, Liu J, et al. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Diabetes 2006;55:A119. Abstract 501-P
96. Rosenstock J, Brazg R, Andryuk PJ, et al. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A132. Abstract 556-P
97. Stein P. Sitagliptin: a novel dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. Presented at: American Diabetes Association - 66th Scientific Sessions, Washington, DC, June 13, 2006
98. Raz I, Hanefeld M, Xu L, et al. Sitagliptin monotherapy improved glycemic control and beta-cell function after 18 weeks in patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A462. Abstract 1996-PO
99. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long acting GLP-1 analogue, on glycaemic control and body weight in subjects widi type 2 diabetes. Diabet Med 2005;22:1016-23
100. Tran P, Yin H, Smith T, Fischer V. Disposition of [14C]LAF237 in rats and humans. Drug Metab Rev 2002;34(Suppl 1):147. Abstract 293
101. He YL, Sabo R, Wang Y, et al. The influence of hepatic impairment on the pharmacokinetics of vildagliptin. Diabetes 2006;55:A469. Abstract 2024-PO
102. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2006.
103. Nadiwani A, Lebeaut A, Byiers S, et al. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes. Diabetes 2006;55(Suppl 1):A113. Abstract 474-P
104. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-57